| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Tokyo 113-0033; 2 Discovery Research Laboratory, Tanabe Seiyaku, Saitama 335-8505; and 3 Institute for Adult Disease, Asahi Life Foundation, Tokyo 160-0023, Japan
To determine the contribution of hyperglycemia to the insulin resistance in various insulin-sensitive tissues of Zucker diabetic fatty (ZDF) rats, T-1095, an oral sodium-dependent glucose transporter (SGLT) inhibitor, was administered by being mixed into food. Long-term treatment with T-1095 lowered both fed and fasting blood glucose levels to near normal ranges. A hyperinsulinemic euglycemic clamp study that was performed after 4 wk of T-1095 treatment demonstrated partial recovery of the reduced glucose infusion rate (GIR) in the T-1095-treated group. In the livers of T-1095-treated ZDF rats, hepatic glucose production rate (HGP) and glucose utilization rate (GUR) showed marked recovery, with almost complete normalization of reduced glucokinase/glucose-6-phosphatase (G-6-Pase) activities ratio. In adipose tissues, decreased GUR was also shown to be significantly improved with a normalization of insulin-induced GLUT-4 translocation. In contrast, in skeletal muscles, the reduced GUR was not significantly improved in response to amelioration of hyperglycemia by T-1095 treatment. These results suggest that the contribution of hyperglycemia to insulin resistance in ZDF rats is very high in the liver and considerably elevated in adipose tissues, although it is very low in skeletal muscle.
glucose toxicity; Zucker diabetic fatty rat; sodium-dependent glucose transporter
This article has been cited by other articles:
|
|
 |
|
  S. Han, D. L. Hagan, J. R. Taylor, L. Xin, W. Meng, S. A. Biller, J. R. Wetterau, W. N. Washburn, and J. M. Whaley Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats Diabetes, June 1, 2008; 57(6): 1723 - 1729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E.-G. Hong, D. Y. Jung, H. J. Ko, Z. Zhang, Z. Ma, J. Y. Jun, J. H. Kim, A. D. Sumner, T. C. Vary, T. W. Gardner, et al. Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1687 - E1696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ordonez, M. Moreno, A. Alonso, R. Fernandez, F. Diaz, and C. Gonzalez Neuroendocrinology/Endocrinology: Insulin sensitivity in streptozotocin-induced diabetic rats treated with different doses of 17{beta}-oestradiol or progesterone Exp Physiol, January 1, 2007; 92(1): 241 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Fujimoto, T. P. Torres, E. P. Donahue, and M. Shiota Glucose Toxicity Is Responsible for the Development of Impaired Regulation of Endogenous Glucose Production and Hepatic Glucokinase in Zucker Diabetic Fatty Rats Diabetes, September 1, 2006; 55(9): 2479 - 2490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Shao, L. Qiao, R. C. Janssen, M. Pagliassotti, and J. E. Friedman Chronic Hyperglycemia Enhances PEPCK Gene Expression and Hepatocellular Glucose Production Via Elevated Liver Activating Protein/Liver Inhibitory Protein Ratio Diabetes, April 1, 2005; 54(4): 976 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Fujimoto, E. P. Donahue, and M. Shiota Defect in glucokinase translocation in Zucker diabetic fatty rats Am J Physiol Endocrinol Metab, September 1, 2004; 287(3): E414 - E423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Duran-Sandoval, G. Mautino, G. Martin, F. Percevault, O. Barbier, J.-C. Fruchart, F. Kuipers, and B. Staels Glucose Regulates the Expression of the Farnesoid X Receptor in Liver Diabetes, April 1, 2004; 53(4): 890 - 898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bajaj, T. Pratipanawatr, R. Berria, W. Pratipanawatr, S. Kashyap, K. Cusi, L. Mandarino, and R. A. DeFronzo Free Fatty Acids Reduce Splanchnic and Peripheral Glucose Uptake in Patients With Type 2 Diabetes Diabetes, October 1, 2002; 51(10): 3043 - 3048. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hawkins, I. Gabriely, R. Wozniak, K. Reddy, L. Rossetti, and H. Shamoon Glycemic Control Determines Hepatic and Peripheral Glucose Effectiveness in Type 2 Diabetic Subjects Diabetes, July 1, 2002; 51(7): 2179 - 2189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hawkins, I. Gabriely, R. Wozniak, C. Vilcu, H. Shamoon, and L. Rossetti Fructose Improves the Ability of Hyperglycemia Per Se to Regulate Glucose Production in Type 2 Diabetes Diabetes, March 1, 2002; 51(3): 606 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Wu, D. A. Okar, C. B. Newgard, and A. J. Lange Increasing fructose 2,6-bisphosphate overcomes hepatic insulin resistance of type 2 diabetes Am J Physiol Endocrinol Metab, January 1, 2002; 282(1): E38 - E45. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Basu, R. Basu, P. Shah, A. Vella, C. M. Johnson, M. Jensen, K. S. Nair, W. F. Schwenk, and R. A. Rizza Type 2 Diabetes Impairs Splanchnic Uptake of Glucose but Does Not Alter Intestinal Glucose Absorption During Enteral Glucose Feeding: Additional Evidence for a Defect in Hepatic Glucokinase Activity Diabetes, June 1, 2001; 50(6): 1351 - 1362. [Abstract] [Full Text]
|
|
|
|
|
|
A. Oku, M. Nawano, K. Ueta, T. Fujita, I. Umebayashi, K. Arakawa, T. Kano-Ishihara, A. Saito, M. Anai, M. Funaki, et al. Inhibitory effect of hyperglycemia on insulin-induced Akt/protein kinase B activation in skeletal muscle Am J Physiol Endocrinol Metab, May 1, 2001; 280(5): E816 - E824. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
